The response rate ( RR ) and disease control rate ( DCR ) were significantly higher in the FOLFOX4 group than in the doxorubicin group ( RR : 8.6 % vs. 1.4 % , p = .006 ; DCR : 47.1 % vs. 26.6 % , p = .0004 ) .